A recent review summarizing the clinical data of both [177Lu]Lu-PSMA and [225Ac]Ac-PSMA PRLT [25] pointed out that the most common toxicity in patients treated with [225Ac]Ac-PSMA is xerostomia, overall higher than that occurring after [177Lu]Lu-PSMA (xerostomia of any grade: 77% vs. 37%), with 17% of G3 or higher grade of dry mouth. This evidence concerns the gene FOLH1 and xerostomia.